Phio Pharmaceuticals Corp. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Phio Pharmaceuticals Corp. on February 10, 2020, covering an event that occurred on February 6, 2020. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Capital Market under the symbol "PHIO."
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate governance and listing status event rather than financial performance.
Material Changes
The primary material event reported is the Company's regained compliance with the Nasdaq Listing Rule 5550(a)(2) regarding the minimum bid price requirement. This compliance was achieved following a one-for-fifty-five reverse split of the Company's common stock, which became effective on January 15, 2020.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. No specific risks or contingencies are detailed in this document other than the prior risk of delisting which has now been resolved.
Investor Verification Checklist
- Verify the effective date of the one-for-fifty-five reverse split (January 15, 2020).
- Confirm the current trading status of PHIO on The Nasdaq Capital Market.
- Review the Company's previous Form 8-K filed on January 14, 2020, for detailed information regarding the reverse split mechanics.